Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

616
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
616
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

2.0K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
2.0K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

659
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
659
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

211
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
211
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.6K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Engaging Rural Practitioners and Community Collaborators in Substance Use Disorder Needs Assessments: Recruitment Approaches Across 4 States.

Journal of public health management and practice : JPHMP·2026
Same author

Dopamine-Enhancing Therapies and Risk of Neovascular AMD Conversion: A Target Trial Emulation.

American journal of ophthalmology·2026
Same author

Longitudinal Trends of Intraocular Lens Dislocation in a Federated Electronic Health Record Network.

Ophthalmic surgery, lasers & imaging retina·2026
Same author

Efficacy of Continuous Pegcetacoplan Treatment for Subfoveal Geographic Atrophy in Age-Related Macular Degeneration: 36-Month Results from OAKS, DERBY, and GALE Open-Label Extension.

Clinical ophthalmology (Auckland, N.Z.)·2026
Same author

Prevalence and incidence of mental health disorders in patients with inherited retinal diseases: a population-based study.

Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus·2026
Same author

Association of Atopic Dermatitis with Retinal Detachment and Postoperative Proliferative Vitreoretinopathy Risk.

Ophthalmology. Retina·2026

Related Experiment Video

Updated: Mar 26, 2026

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
05:18

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome

Published on: May 26, 2023

2.0K

Corticosteroid implants for chronic non-infectious uveitis.

Christopher J Brady1, Andrea C Villanti, Hua Andrew Law

  • 1Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

The Cochrane Database of Systematic Reviews
|February 12, 2016
PubMed
Summary
This summary is machine-generated.

Steroid implants may prevent uveitis recurrence but increase risks for cataract and glaucoma surgery. More research is needed to confirm if implants are superior to traditional therapies for non-infectious uveitis.

More Related Videos

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

1.2K
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

33.7K

Related Experiment Videos

Last Updated: Mar 26, 2026

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
05:18

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome

Published on: May 26, 2023

2.0K
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

1.2K
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

33.7K

Area of Science:

  • Ophthalmology
  • Inflammatory Diseases
  • Medical Treatments

Background:

  • Uveitis, a group of intraocular inflammatory diseases, is a significant cause of vision loss.
  • Corticosteroids are the primary treatment for non-infectious uveitis.
  • Steroid implants offer a localized drug delivery method for ocular conditions.

Purpose of the Study:

  • To evaluate the efficacy and safety of steroid implants for chronic non-infectious posterior, intermediate, and panuveitis.
  • To compare steroid implants with standard-of-care treatments for uveitis.

Main Methods:

  • Systematic search of multiple databases for randomized controlled trials.
  • Inclusion of studies comparing fluocinolone acetonide (FA) or dexamethasone implants with standard care.
  • Data extraction and bias assessment by two independent reviewers.

Main Results:

  • Two studies (401 participants) compared FA implants with standard care.
  • FA implants likely reduce uveitis recurrence (moderate-quality evidence).
  • Increased risks of cataract and intraocular pressure-lowering surgery observed with FA implants (moderate-quality evidence).

Conclusions:

  • Current evidence is insufficient to declare steroid implants superior to systemic therapy for non-infectious uveitis.
  • Steroid implants are associated with higher risks of post-operative cataract and glaucoma surgery.
  • Heterogeneity in study design and outcome measures limits definitive conclusions.